Literature DB >> 20425409

Prognostic factors in low-grade non-Hodgkin lymphomas.

Massimo Federico1, Stefano Molica, Monica Bellei, Stefano Luminari.   

Abstract

Low-grade non-Hodgkin lymphomas were once considered as a heterogenous group of lymphomas characterized by an indolent clinical course. Today, low-grade non-Hodgkin lymphomas are classified as a group of 10 distinct entities, each characterized by unique clinico biologic features. Follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma, and marginal zone lymphoma are the most-investigated subtypes. Several studies have been performed to identify prognostic factors specific for each subtype in an effort to help clinicians in treatment decisions. The field of biologically specific associated parameters holds great potential but requires more research and work to produce translational results.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20425409     DOI： 10.1007/s11899-009-0027-0

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  59 in total

1.  Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients.

Authors:  F Berger; P Felman; C Thieblemont; T Pradier; L Baseggio; P A Bryon; G Salles; E Callet-Bauchu; B Coiffier
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

2.  Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP.

Authors:  Minna Taskinen; Marja-Liisa Karjalainen-Lindsberg; Sirpa Leppä
Journal:  Blood       Date:  2008-02-28       Impact factor: 22.113

3.  Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi.

Authors:  M Federico; U Vitolo; P L Zinzani; T Chisesi; V Clò; G Bellesi; M Magagnoli; M Liberati; C Boccomini; P Niscola; V Pavone; A Cuneo; G Santini; M Brugiatelli; L Baldini; L Rigacci; L Resegotti
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma.

Authors:  Tomás Alvaro; Marylène Lejeune; Francisca I Camacho; Ma Teresa Salvadó; Lydia Sánchez; Juan F García; Carlos Lopez; Joaquín Jaén; Ramón Bosch; Lluis E Pons; Carmen Bellas; Miguel A Piris
Journal:  Haematologica       Date:  2006-12       Impact factor: 9.941

6.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

Authors:  Pedro Farinha; Hamid Masoudi; Brian F Skinnider; Karey Shumansky; John J Spinelli; Karamjit Gill; Richard Klasa; Nicolas Voss; Joseph M Connors; Randy D Gascoyne
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

7.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

Authors:  Robert Marcus; Kevin Imrie; Andrew Belch; David Cunningham; Eduardo Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; Joäo Raposo; Andrew Jack; Paul Smith
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

8.  Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

Authors:  William G Wierda; Susan O'Brien; Xuemei Wang; Stefan Faderl; Alessandra Ferrajoli; Kim-Anh Do; Jorge Cortes; Deborah Thomas; Guillermo Garcia-Manero; Charles Koller; Miloslav Beran; Francis Giles; Farhad Ravandi; Susan Lerner; Hagop Kantarjian; Michael Keating
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

9.  Splenic marginal zone lymphoma: a prognostic model for clinical use.

Authors:  Luca Arcaini; Mario Lazzarino; Nora Colombo; Sara Burcheri; Emanuela Boveri; Marco Paulli; Enrica Morra; Marcello Gambacorta; Sergio Cortelazzo; Alessandra Tucci; Marco Ungari; Achille Ambrosetti; Fabio Menestrina; Lorella Orsucci; Domenico Novero; Alessandro Pulsoni; Maurizio Frezzato; Gianluca Gaidano; Daniele Vallisa; Viviana Minardi; Claudio Tripodo; Vincenzo Callea; Luca Baldini; Francesco Merli; Massimo Federico; Vito Franco; Emilio Iannitto
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

10.  Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.

Authors:  Wolfram Klapper; Eva Hoster; Lars Rölver; Carsten Schrader; Dirk Janssen; Markus Tiemann; Heinz-Wolfram Bernd; Olaf Determann; Martin-Leo Hansmann; Peter Möller; Alfred Feller; Harald Stein; Hans-Heinrich Wacker; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann; German Ott
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544
View more
  5 in total

Review 1.  Therapeutic cancer vaccines: the latest advancement in targeted therapy.

Authors:  Marijo Bilusic; Ravi A Madan
Journal:  Am J Ther       Date:  2012-11       Impact factor: 2.688

2.  Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma.

Authors:  Pınar Cömert; Abdulkerim Yıldız; Murat Yıldırım; Hacer Berna Afacan Öztürk; Çiğdem Pala; Murat Albayrak; Meltem Aylı
Journal:  Indian J Hematol Blood Transfus       Date:  2019-08-06       Impact factor: 0.900

Review 3.  Current role of FDG PET/CT in lymphoma.

Authors:  Lale Kostakoglu; Bruce D Cheson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-12       Impact factor: 9.236

Review 4.  Prognostic assessment in patients with indolent B-cell lymphomas.

Authors:  Luca Arcaini; Sara Rattotti; Manuel Gotti; Stefano Luminari
Journal:  ScientificWorldJournal       Date:  2012-07-31

5.  Clinical significance of sIL-2R levels in B-cell lymphomas.

Authors:  Noriaki Yoshida; Miyo Oda; Yoshiaki Kuroda; Yuta Katayama; Yoshiko Okikawa; Taro Masunari; Megumu Fujiwara; Takashi Nishisaka; Naomi Sasaki; Yoshito Sadahira; Keichiro Mihara; Hideki Asaoku; Hirotaka Matsui; Masao Seto; Akiro Kimura; Koji Arihiro; Akira Sakai
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.